Contact
Home • Our expertise • Centers of Excellence • Advanced Clinical Technologies

Advanced Clinical Technologies.

Take your advanced clinical technology engagements to the next level.

Get in touch with an expert

What we do.

Our team brings world-class expertise in novel technologies, especially cell and gene therapy, offering a proven track record and an unmatched level of experience to advanced technology manufacturers. With a dedicated focus on cell and gene therapy for more than 10 years and experience across 20 disease areas, our leaders are equipped with the tools, resources, and strategic and technical excellence to take advanced clinical technology and CGT engagements to the next level.

While these technologies can offer transformative benefits to patients and extraordinary clinical promise, there are many challenges to successful commercialization. We leverage scientific, clinical, and commercial assessments and expertise in disease areas, including hematologic malignancies, solid tumors, neurology, ophthalmology, cardiology, immunology and non-malignant blood disorders.

Learn about our services

The breadth of technologies we support include:

  • Allogeneic cellular medicine
  • Autologous cellular medicine
  • Gene therapy
  • Radioconjugate/Radioligand therapy
  • Antibody-drug conjugates
  • Oncolytic viruses
  • MRNA, DNA-editing, RNA-editing, and RNAi
  • Cancer (therapeutic) vaccines
  • Engineered peptides

What sets us apart.

World-class expertise in novel technologies and CGT

Our experts hold a rich understanding of both the business and the science, offering unique perspectives on the intersection of each space, allowing us to engage technical discussions and uncover a level of detail that others may miss.

Access to stakeholders across the ecosystem

Our research does not stop with HCPs. Some of our research samples include stakeholders from disease therapy experts and nurse navigators to hospital CFOs and more.

Robust research toolbox for data collection

We have access to a deep roster of third–party sample partners, including our internal panel of HCPs, payers, andhigh–level KOLs, plus technologies that help us reach new stakeholders.

A pioneer in CGT strategy.

8

Partners and principals routinely leading CGT engagements

20

Unique disease areas

30

Engagements per year over past five years

20

CGT manufacturers across cellular and non-cellular gene therapies

Some of our most notable Cell and Gene Therapy highlights:

  • Guided the prioritization of targets and technologies for cell therapies
  • Developed the go-to-market model for the first CAR-T launch
  • Created strategic plans through custom insight development work
  • Designed commercial site footprints for multiple CGT products
  • Advised on pricing, access, and value/evidence strategy for multiple CAR-T products
  • Mapped business processes for delivering the first cell therapy for solid tumors in the US
  • Developed long-term pipeline and portfolio strategies for key CGT players

Our experience in Cell & Gene Therapy spans a wide array of functional areas.

Scientific and clinical strategy

Commercial strategy

Pricing and access strategy

Business development and portfolio planning

Medical and scientific affairs

Operations and customer experience

Our Advanced Clinical Technologies lead.

Joseph Feingold

Partner, Portfolio, Licensing & Development Practice Lead & Head of Advanced Technologies Center of Excellence

Read bio

About Joseph.

A neuroscientist turned biotech strategy expert with deep experience navigating complex challenges in global markets, Joseph combines scientific and entrepreneurial skillsets to perform rigorous analysis and deliver critical insights to biopharma, diagnostics, and medical device leaders. Joseph supports a range of clients across therapeutic areas and modalities, with particular focus on hematology / oncology, neurology, and rare diseases, developing strategies for pipeline products and portfolios to guide BD, clinical development, and commercialization. An expert on novel technologies, Joseph heads Putnam’s Center of Excellence on advanced technologies, including cell and gene therapies, requiring sophisticated hospital-based administration and development of new commercialization models.

Featured case study

Long-term strategy for Cellular Therapy

Putnam was engaged to support the development of a 10-year strategy for cellular therapy.
View all case studies
Featured

Long-term strategy for cellular therapy

The organization engaged Putnam to support the development of 10-year strategy, focused on continuous innovation across all aspects of the business.

Read more

Latest thinking.

Get the latest insights and perspectives from our experts.

View all of our resources

“Personalized” battle against GI cancers: Highlights from ASCO GI 2024

Personalized medicine is revolutionizing the field of oncology, and gastrointestinal (GI) cancers are at the forefront of this exciting development.

Read more

Spotlight on antibody drug conjugates (ADCs)

ADCs continued to be a spotlight at ESMO 2023. The team shares its key value drivers and associated limitations.

Read more

Long-term strategy for cellular therapy

The organization engaged Putnam to support the development of 10-year strategy, focused on continuous innovation across all aspects of the business.

Read more

Unlocking the promise of cell therapies for solid tumors: Opportunities and challenges

Our cell and gene therapy experts offer a deep analysis on the current opportunities and challenges of cell therapies for solid tumors.

Read more

Get in touch.

Looking to get in touch with an expert or team member?

Tell us how we can help.

Contact us today